Orthotopic human prostate tumour models in at hymic nude mice are regarded as being most suitable for fundamental and pre-clinical research on prostat e cancer. T he anatom ic localizat ion of the tum our in the pelvis, however, provides little possibility for monitoring tumour growth or regression. To assess time-related changes in orthotopic tumour volume, we applied transrectal ultrasonography (T RUS) to the murine prostate. T his technique has the advan tages of allowing accurate monitoring of tumours during therapeutic manipulations and a reduction of anim al use due to a reduction of sacri®cing endpoints. To validate the T RUS method, the mouse prostate reconstitution model, RM-9, and the prostate-speci®c antigen (PSA) producing human prostate cancer xenograft PC-346 were used. Volumetric calliper measurements were performed with a 30 MHz ultrasound probe designed for intra-arterial use in humans. Tumour weight, determined at various time-points, was found to be closely related to act ual tumour weight (Rˆ0:99 ) and, in the PC-346 model, to the level of PSA in the plasma. Furthermore, the interobserver variation for T RUS was low for tum ours above 50 mg. T hus, T RUS for murine prostate tumours proves to be an accurate, reproducible and sensitive method.
In western males, prostate cancer accounts for the highest incidence of all solid tumours, and is the second largest cause of male cancer death (Potosky e t a l. 1995). As a result, a tremendous effort is being put into research on prostate cancer using experimental and pre-clinical models. T he available in vitro models differ in their androgen sensitivity/dependence, different iat ion grade (review: Navone e t a l. 1998 ) and, when grown in athym ic nude mice as subcutaneous tumour xenografts, in metastati c capacity (review: van Weerden & Romijn 2000 ) .
Lat ely, the use of orthotopically growing tum ours has become more popular, because the orthotopic site offers a more natural environment for the growing tumour compared to its subcutaneous counterpart (Rubenstein e t a l. 1995, Rembrink e t a l. l997, Lein e t a l. 2000 ). T he presence of mouse stromal prostate cells may in¯uence tum our growth and differentiat ion by secretion of growth factors, induction of angiogenesis and, possibly, metastasis (Chang e t a l. 1999 , Wang e t a l. 1999 . With orthotopic prostate tumours in mice, tumour cells are preferably injected into the dorsolateral prostate lobes during a small laparotom y under general anaesthesia (Rem brink e t a l. 1997).
A major disadvan tage of the orthotopic model, compared to subcutaneous tumours, is the relative inaccessibility of the tumour in the murine pelvis. When, as a result of therapeutic manipulations, tumour growth or regression are to be assessed, direct abdom inal palpation of the tum our does not offer an accurate or reproducible result. As an alternative, the time-controlled sacri®ce of anim als may be analysed; however, this is not preferable because of biological variations of individual tumours and the loss of anim al lives.
For PSA-producing human prostate xenografts, the determination of PSA in the plasma of the anim al is a feasible method for monitoring tumour growth. Since mice do not produce PSA, all traces of PSA in the blood are derived from the tumour. T his method is very sensitive, but is restricted to PSA-producing tumours and is dependent on androgen levels in the host. Furthermore, repeated retro-orbital punctions are demanding on the animals and real-ti me monitoring is impossible due to the time taken up by the analysis of the PSA levels.
In man, the size of the prostate gland is most accurately measured by transrectal ultrasonography (Terris e t a l. 1992, Bangm a e t a l. 1996). Various methods have been analysed to calculate prostate volume using ultrasound calliper measurements. A lubricated 7.5 MHz ultrasound probe visualizes the prostate in two perpendicular planes, revealing maximal length, width, and height of the gland. Furthermore, ultrasound imaging of the prostate may indicat e the presence of benign hyperplasia or malignanc y. Obviously, the human transrectal ultrasound device cannot be applied to mice due to their size and ultrasound penetration depth, whereas transabdom inal ultrasonography of the prostate is limited by the disturbanc e of intra-intestinal gas. We, therefore, used a small ultrasound probe, normally applied in endovascular imaging (Gussenhoven e t a l. 1989 ) , to visualize and measure the murine prostate through the rectum .
We report on the validation of transrectal ultrasonography of the murine prostate using the 30 MHz, 4.3 F imaging catheter on the mouse prostate reconstitution model (MRP, T hompson e t a l. 2000) and on the human PSA-producing PC-346 xenograft .
Materials and methods

Anim a ls
Adult male C57BL/6 mice (6±7 weeks old, 25±30 g bodyweight, speci®ed pathogen free; Harlan, Horst, T he Netherlands) and adult male athym ic nude mice (NMRI nu/ nu, 6±7 weeks old, 25±30 g bodyweight, speci®ed pathogen free; Harlan) were allowed to acclim atize for at least 2 days in an isolated system (medium-sized stainless steel isolator; Beijer and Eggelaar, Maarsenbroek, T he Netherlands) under standardized conditions, with a temperature of 22 C ( 1 C ), 50% ( 5% ) humidity, and an applied over-pressure of 75 Pa. Night/day conditions were controlled by arti®cial lighting (lights on 07:00 h, lights out 19:30 h). Animals were kept in 15615645 cm cages, with maximally four animals per cage, on sawdust (Woody-C lean, type BK8/15; BM I, Helmond, T he Netherlands). Sterilized food (Hope Farm s BV, Woerden, T he Netherlands) and sterilized acidi®ed drinking water were supplied a d lib itum . Experiments were performed during day-tim e hours in ā ow-cabinet (Cl ean Air, Woerden, T he Netherlands) connected to the isolator.
All the experiments were performed in agreement with T he Netherlands Experiments on Animals Act (1977 ) and the European Convention for the Protection of Vertebrate Animals used for Experimental Purposes (Strasbourg, 18 March 1986 ) . Approval was obtained from the University Animal Committee (DEC ).
O rth o to pic pro sta te tum o ur m o d e ls
T he RM-9 tumour of the mouse prostate reconstitution model and the orthotopic human prostate tumour PC-346C were chosen to validate the T RUS method. During the experiments, the maxim al allowable tumour size was set at 1000 mg: below this weight mice did not suffer from tumour burden, whereas mice bearing larger tumours showed signs of fatigue and weight loss. Obstructi on of both ureters and subsequent retention of urine in the draining kidney beds would result in acute death.
RM-9 cells were received as a gift; cells of the RM series are part of the mouse prostate reconstitution model (MRP, T hompson e t a l. 1989), which have been derived through retroviral transduction of p53 knockout mouse urogenital sinus cells with m yc and ra s oncogenes. T he RM-9 orthotopic tum our has a high tak e-rat e, a short lag-phase of approxim ately 7 days, and a short tumour doubling-ti me of 2±3 days. RM-9 cells are maintained in vitro in tissue culture¯asks (Falc on, Becton Dickinson Labware, Frank lin Lak es, NJ, USA) in low glucose (1000 mg/l) DMEM (Gibco BRL, St Gaitersburgh, MD, USA), supplemented 1:1 with HAM's F12 (Biowhittaker Europe, Verviers, Belgium ), 10% foetal calf serum (Bodin co BV, Alkmaar, T he Netherlands), 100 U/ml penicillin and 100 mg/ml streptomycin (both from Biowhittaker). Cells were grown at 37 C in a humidi®ed atmosphere of 5% CO 2 in air, and were split twice weekly by trypsinization followed by seeding at approxim ately 20% con¯uency.
T he human prostate cancer cell line PC-346C is developed in our laboratory from the PC-346 xenograft. PC-346 originates from tissue taken from a non-progressive prostate cancer patient, which was obtai ned by transurethral resection of the prostate. Both the xenograft and its related cell line are androgen responsive, secrete PSA and harbour the wild type androgen receptor. PC-346C cells are cultured in a modi®ed medium based on DMEM/F12 (1:1; Gibco BRL) supplemented with 2% foetal calf serum (Bodinc o BV), 1% IT S-G (Gibco BRL), 20 ng/ml epidermal growth factor (Sigma, St Louis, MO, USA) and some smaller additions. Cells were grown under conditions similar to those indicated for the RM-9 cell line and were split once a week by trypsinization, followed by seeding at approximately 20% con¯uence.
Orthotopic injections into the dorsolateral prostate were performed as described before (Rembrink e t a l. 1997 ) with some minor modi®cati ons. Brie¯y, cells were harvested by trypsinization and resuspended at a density of 5000 cells in 20 ml PBS (Biowhittaker) for RM-9 cells or at a density of 500 000 cells per 20 ml PBS for PC-346C cells. Twenty microlitres of the cell suspensions were injected into one of the dorsolateral lobes of the prostate.
Tra nsre cta l ultra so no gra ph y o f th e m urine pro sta te
An intravascular 30 MHz ultrasound catheter (Princeps 4.3F CCS 0.035'', EndoSonics Europe BV, Rijswijk, T he Netherlands), from which the monorail connector was removed, was used as an imaging probe. T he system has an axial resolution (depth) of 100 mm, a radial resolution (beam width ) of 200 mm, and a circular display of 500 lines. Images were printed on a Video Graphics Printer (Sony Electronics, Tokyo, Japan ).
Mice were anaesthetized with diethylether (highest purity; Vel, Leuven, Belgium ). T he cat heter was lubricated with ultrasound gel (Aquasonic 100; Parker Laboratories INC, Orange, NJ, USA) and introduced into the rectum of the animal at a depth of l6±20 mm. T he prostate and bladder were visualized on a monitor and, whenever im aging was disturbed by rectal air, the rectum was¯ushed with saline (NPBI BV, Emmer Compascuum, T he Netherlands) applied through the shaft of the catheter. T he largest cross-section of the prostate was visualized and the im age was frozen. T he maximal height was de®ned as the largest calliper distance measured in a centrifugal direction from the probe, while the maxim al width was determined as perpendicular to the height. Tumour volume was calculated according to a form ula approximati ng the volume of a sphere (d ia m e te r 3 6p/6, using the average of maxim al height and width as diameter). Tum our weight was set to be equal to tumour volume, based on a density of 1 mg/ml. Actual tum our weight was determined after sacri®ce of the mouse by cervical dislocation and the sharp dissection of the dorsolateral prostate tumour.
PSA d e te rm ina tio n Blood (0.3 ml) was obtained through retroorbital punction and collected in a heparin tube (Sarstedt, Nu È mbrecht, Germany). Plasm a was obtained after centrifugation for 5 min at 1500 6 g and PSA concentrat ion was determined by an automat ed enzyme-linked immunosorbent assay (ELISA) (Elecsys total PSA Immunoassay; lower detection lim it 0.002 ng/ml; Roche Diagnostics GmbH, Mannheim, Germany).
Va lid a tio n o f tra nsre c ta l ultra so no gra ph y fo r m urine pro sta te s T he ultrasound technique was validat ed on basis of accuracy, reproducibility, and sensitivity. To correlate actual and T RUS calculated tum our weights at various tumour sizes, 18 orthotopic RM-9 tum ours were set up and, at different time-points at a 2±3 day interval, three anim als were sacri®ced. At each time-point, ultrasound measurements of the tumour size were performed prior to sacri®ce. Both parameters were correlated using regression analysis (SPSS, SPSS Inc., Chicago, IL, USA). All ultrasonographic measurements, including measurements in anim als that would not be sacri®ced, were performed by two individuals in a blinded set-up. Statistical analysis (Wilcoxon signed rank test; distribution of the differences was not exactly normal) on these data determined the reproducibility (interobserver variation ) of the method.
Assessment of the sensitivity of the T RUS method, i.e. at what size the initiated tumour growth could be determ ined, was achieved by direct comparison of the ultrasound technique with plasma PSA level analysis in the PC-346C model. Plasm a PSA levels and actual tum our weight were correlated in 15 PC-346C bearing anim als in order to validat e and calibrat e the plasma PSA method. Subsequently, tumour growth curves, determined by both the plasma PSA and T RUS techniques, were related in four mice.
Results
U ltra so no gra ph y o f th e m urine pro sta te
Clear ultrasound images, which related well to the macroscopic anatom y (Fig 1a) , could be generated. T he¯uid-®lled bladder and the sacrum served as easily recognizable markers. Also, the urethra could easily be visualized as a tube situated upon the rectum (not shown). At the position where the urethra connects to the bladder the urethra disappears from the ultrasound image, which served as a landmark for the caudal boundaries of the dorsolateral prostate lobes. Although the normal prostat e was somewhat dif®cult to identify due to its limited volume and its non-spheroidal shape (Fig 1b) , changes caused by intraprostati c tumour growth could easily be visualized (Fi g 1c ). Tumours above 1000 mg were more dif®cult to visualize completely due to the limited penetration depth of the imaging probe (Fig 1d) . In the range between 50 and 1000 mg, in which the sizes of most experimental tumours lie, accurate im aging could be performed.
Ac c ura cy a nd re pro d ucib ility o f TRU S
Correlation of actual tumour weight with T RUS calculated tumour weight (Fig 2) showed a correlation coef®cient (R) of 0.99, indicating a very strong correlation. However, the slope of the correlation line was 0.80, with a 95% con®dence interval ranging from 0.73 to 0.86, indicating a systemic underestimation of tumour weight. T he y-axi s intercept was 12 mg with a 95% con®dence interval that ranged from ¡ 11 to 36 mg.
Inter-observer variation was assessed by comparing two independent T RUS measurements on 53 tum ours below 1000 mg (Fig 2) . No signi®cant differences between the two observers could be found (Pˆ0.53, Wilcoxon signed rank's test), alt hough the percentual differences could be substantial in the range below 50 mg. In this range however, large percentual differences resulted in small absolute differences.
Se nsitivity o f TRU S
Shortly after orthotopic injection of PC-346C cells, when the tum our is still in the lag-ph ase, low levels of PSA can be detected in the plasma. When the tumour enters the log-phase of the growth curve, an increase in PSA level is observed. T herefore, PSA plasma ultrasound method (right panel) . Using the RM-9 orthotopic tumour model, TRUS estimated tumour weight was correlated with the actual tumour weight. Regression line (solid), 95% con dence interval lines (dotted), and parameters are shown (left panel). Using the same tumour model, interobserver variation of the TRUS method was assessed. Measurements of both observers are depicted on logarithmic scales. The line of identity (dashed) and parameters are shown (right panel) levels clearly determine the point of onset of tumour growth. To compare orthotopic growth curves generated by the T RUS and the PSA plasma level methods, PSA plasma levels and actual tum our weight were correlated and calibrated ®rst (Fig 3) . Plasma PSA plasma levels correlated closely to actual tumour weight (Rˆ0.98 ). T he slope of the calibration line was 5.1 with a 95% con-®dence interval ranging from 4.5 to 5.7, and its y-axis intercept was 51 mg with a 95% con®dence interval that ranged from ¡ 36 to 138 mg.
Tum our growth curves determined by the T RUS and the PSA plasma level methods were aligned for four different mice bearing orthotopic PC-346C tum ours. In Fig 3, the growth curves of one representative tum our are depicted. When PSA plasma levels increased steeply (between days 35 and 42 ), T RUS calculated tumour weight also increased. T his indicates a comparable sensitivit y of both the T RUS and the plasma PSA methods.
Discussion
Transrectal ultrasonography of the murine prostate offers an excellent tool for monitoring sizes of orthotopic prostat e tum ours. T he correlation (R) between T RUS calculated tumour weight and actual tum our weight was found to be 0.99. T he slope of the regression line is signi®cantly lower than one (0.80 0.03 ), indicating an underestimation of actual tumour weight. Although the reason for this is unclear, the high correlation implies the technique to be very accurate, and it was decided not to correct for the systemic under-estimation.
T he presented data show that the ultrasound technique is also accurate when used by different observers, while its learning curve was found to be short. No systemic difference was observed when two observers independently measured the sam e tum ours (Pˆ0.53). However, large percentual differences were found between both observers when smaller tumour sizes were assessed. Such differences are most likely due to the dif®culties in visualizing small tumours and the normal prostate. T he absolute weight differences in these small structures were, however, small.
T RUS of murine prostat e tum ours provides a method for the early recognition of orthotopic tumour growth from a tumour size of approximately 40 mg onwards. Early recognition of growth is bene®cial in terms of early treatm ent possibilities, time-matc hing of different tum ours and selection of anim als in which tum ours are growing. Although the take of orthotopically initiat ed murine prostate tumours at our institution, including that of the orthotopic PC-346C model, is over 90% , the slow growing models on average take more than 4±5 weeks before they become palpable in the abdom en. Compared to palpation, the time-point of ®rst recognition by T RUS is at least one week earlier. As an alternative, plasm a PSA may serve as an indicator of growth. Our study of the PC-346C model showed that plasma PSA levels also correlate closely (Rˆ0.98 ) to actual tum our weight. However, the plasma PSA method is more demanding and more invasive than the ultrasound method. Furthermore, plasma PSA can only be determined using PSA-producing tumours such as PC-346C and LNCaP. When using the plasma PSA method, PSA can be detected at an early stage, but a signi®cant increase in PSA, indicative of progressive growth, might only be seen at 3±4 weeks after injection. An increase in ultrasound estimated tumour weight can be expected at approximately the same tim e (Fig 3) .
T he main advantage of the T RUS method lies in the extra information on orthotopic tumour growth in individual mice over time. Previously, mice had to be sacri®ced to get inform ation on orthotopic tumour weight and, in order to create a growth curve, mice had to be sacri®ced at various time-points. Using ultrasonography, a growth curve can be obtained from one speci®c anim al: therefore the biological behaviour of an individual tumour can be studied and experimental results will be less compromised by the need to combine data of time-m atched tum ours from other mice. Besides the experimental advan tage of follow-up on individual tumours, there is an obvious advant age in the reduction of the number of mice needed to perform experiments. It is feasible to include time intervals of at least 2 days, as at that frequency the temporary anaesthesia does not affect survival or ®tness of the anim als. It is estimated that the costs of in vivo experiments for prostate cancer might be reduced by 50% or more. Furthermore, T RUS also indicates local tum our load more effectively than palpation, allowing the guidelines for maximal tumour weight, indicat ed in regulations for experimental anim al conditions, to be met more strictly.
Early recognition and follow-up of orthotopic tumours mak es the PC-346 xenograft model an excellent tool for the application of gene therapy, as has been performed in the orthotopic murine prostate tum our model of RM cells. In that model, small orthotopic prostate tumours have been injected effectively with cytotoxic (Hall e t a l. 1997 ) or im munostimulatory adenoviral vectors (Nasu e t a l. 1999 ) under an operation microscope. T RUS may provide a method which indicates the optimal tim e of individual laparotom y for performing intratum oural injection and, as discussed above, a method for monitoring individual tum our responses to treatm ent.
